Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLCPUBT·Jul 10 at 09:18 AM688578+1.68%
Allist released its performance for the first three quarters, with a net profit attributable to the parent company of 1.616 billion yuan, a year-on-year increase of 52.01%Zhitong·Oct 28, 2025 at 05:01 PM688578+1.68%
Allist: The net profit for the third quarter was 565 million yuan, a year-on-year increase of 38.77%Zhitong·Oct 28, 2025 at 05:35 AM688578+1.68%
Allist conducted a block trade today at a discount, with 488,700 shares traded and a transaction amount of 51.1327 million yuanZhitong·Sep 11, 2025 at 04:29 AM688578+1.68%
Allist today conducted a block trade of 520,000 shares at a discount, with a transaction amount of 54.5532 million yuanZhitong·Sep 2, 2025 at 04:28 AM688578+1.68%
Today, a total of 99 stocks had block trades, with a total transaction amount of 2.8 billion yuanZhitong·Sep 1, 2025 at 04:39 AM688578+1.68%002625+2.10%
Allist today conducted a block trade at a discount, with 5.3165 million shares traded, totaling 566 million yuanZhitong·Sep 1, 2025 at 04:28 AM688578+1.68%
Buy back InnoCare Pharma and increase holdings in Allist, European-China Fund's Gran: The innovative drug industry chain is expected to continue driving industry growthWallstreetcn·Aug 29, 2025 at 11:55 PM688428+0.70%09969-0.78%
Winning a cancer-fighting pill, Nantong contractor rakes in 11 billionWallstreetcn·Aug 28, 2025 at 09:10 PM688578+1.68%
Allist released its semi-annual performance, with a net profit attributable to the parent company of 1.051 billion yuan, a year-on-year increase of 60.22%Zhitong·Aug 26, 2025 at 04:14 AM688578+1.68%
ABBISKO-B: The IND application for the oral PD-L1 inhibitor ABSK043 from ABBISKO Pharmaceuticals in combination with Allist's KRAS G12C inhibitor citric acid gorasib tablets for the treatment of NSCLC has been approved by CDEZhitong·Aug 20, 2025 at 06:29 AM688578+1.68%02256-4.15%
Allist: Employee stock ownership platform plans to reduce its holdings by no more than 3%Zhitong·Aug 8, 2025 at 06:21 AM688578+1.68%
Allist: The indication for second-line treatment of EGFR20 exon insertion mutation NSCLC with Furmonertinib tablets is proposed to be included in the priority review processZhitong·Jul 9, 2025 at 04:36 AM688578+1.68%
Allist: The new drug application for Citric Acid Golai Resai Tablets has been approvedZhitong·May 22, 2025 at 03:54 AM688578+1.68%
